Bifidobacterium spp., a genus within the Actinobacteria phylum, are among the earliest colonizers of the human gut, particularly prevalent in pregnant mothers and infants.
These non-spore-forming, Gram-positive, anaerobic probiotics also inhabit the mouth and vagina.
Known for their probiotic properties, Bifidobacterium spp. are commonly included in functional foods. They play a critical role in human carbohydrate metabolism, producing short-chain fatty acids like acetate, which benefit gut health, cardiovascular health, and metabolic processes.
Additionally, Bifidobacterium spp. help prevent and treat various conditions, including colorectal cancer, diarrhea, and inflammatory bowel diseases, by competing with pathogens and enhancing immune responses.
Their genetic adaptations, revealed through genome sequencing, contribute to their survival and competitiveness in the human gastrointestinal tract.
Bifidobacterium spp. are also linked to improved psychological health, reducing stress, anxiety, and depression, and are notably lower in individuals with autism, contributing to ASD symptoms through reduced GABA synthesis.
Bifidobacterium spp. is a specific genus of bacteria within the Actinobacteria phylum. They are a genus of non-spore-forming, Gram-positive, anaerobic probiotics, and one of the earliest microbes to colonize the human gut, often found in pregnant mothers and infants. [5.]
They are known to colonize the human gastrointestinal tract including the mouth, as well as the vagina. [24.]
Known for their probiotic properties, bifidobacteria strains are commonly included in functional foods. [18.]
Bifidobacterium spp. are among the first microbes to colonize the human gut; they exert significant health benefits.
Known for their probiotic properties, bifidobacteria are commonly included in functional foods.
Bifidobacterium spp. are important in human carbohydrate metabolism: they produce short-chain fatty acids like acetate which benefit the host by modulating gut health, improving cardiovascular health, and supporting metabolic processes.
Additionally, bifidobacteria are involved in competitive exclusion of pathogens and have been shown to help prevent or treat conditions like colorectal cancer, diarrhea, necrotizing enterocolitis, and inflammatory bowel disease.
Bifidobacterium spp.'s survival and competitiveness in the human gastrointestinal tract are attributed to specific genetic adaptations revealed through genome sequencing, such as their metabolic capabilities and evasion of the host's immune system.
Increasingly, the benefits of Bifidobacterium spp. for gut and overall health are demonstrated in research. While specific strains are mentioned here, many of these benefits are widely attributed to Bifidobacterium spp. as a genus.
Bifidobacterium spp. help in preventing diarrhea, improving lactose intolerance, and modulating the immune system. [24.]
Ingestion of fermented milk products containing B. animalis has been reported to improve colon regularity. Certain bifidobacterial strains have been linked to alleviation of constipation. [18.]
Bifidobacterium spp. has also shown benefit in preventing oral inflammations and dental caries. [5.]
Bifidobacterium spp. compete with pathogens in the gut, protecting against infections. [5., 24.]
Their ability to adhere to the gut lining through glycoprotein-binding fimbriae aids in persistence and colonization in the gastrointestinal tract. [24.]
Other examples include B. longum ATCC 15708 (against E. coli, Salmonella), B. lactis BB-12 (reduces respiratory tract infections in children), and B. animalis AHC7 (prevents acute diarrhea in dogs).
Bifidobacterium spp. inhibit the replication of viruses such as Coxsackievirus B3 and rotavirus. [5.]
B. longum subsp. infantis CECT 7210 and B. breve K-110 have been found effective in inhibiting rotavirus, which causes diarrhea in infants. [3., 6.]
A commercial probiotic formula containing B. bifidum and Streptococcus thermophiles significantly reduced antibiotic-associated diarrhea in infants. [7.]
Bifidobacterium spp. enhance immune response, inhibit cancer cell growth, and alter gut conditions to prevent tumor development. [5.]
Studies using murine models suggest that a combination of prebiotics and bifidobacteria may reduce the occurrence of carcinogen-induced cancerous cells.
B. animalis has shown anti-mutagenic activity, and strains of B. longum and B. breve provide protection against DNA damage from carcinogens. [18.]
B. longum has also been shown to inhibit colon and liver tumors in rats. [5.]
Bifidobacterium spp. has been shown to enhance immune responses, increase levels of beneficial antibodies, and promote regulatory T cells. [5.]
One animal study demonstrated that Bifidobacterium spp. supplementation in lactating mice enhances local IgA production in both the intestine and milk, contributing to improved immune protection against food antigens and possibly preventing allergic sensitization. [10.]
B. longum produces a serine protease inhibitor (serpin) that may contribute to its immunomodulatory activity. [24.]
B. breve M-16V has been shown to regulate immune balance. [5.]
B. adolescentis IM38 has also been shown to inhibit NF-κB activation, and B. bifidum ATCC 29521 may restore the intestinal microbiome. [5.]
Bifidobacterium spp. act as psychobiotics, reducing stress, anxiety, and depression. [5.]
Strains of B. adolescentis shows anti-depressive and anti-anxiety properties by producing gamma-aminobutyric acid (GABA), a central nervous system inhibitory neurotransmitter; by regulating gut immune responses and microbiota composition, and by modulating the benzodiazepine site of the GABAA receptor and stress-related cytokine expression. [8., 13., 14.]
B. breve CCFM1025 exhibits antidepressant-like effects in chronically stressed mice due to its ability to metabolize various carbohydrates and produce neuroactive metabolites like tryptophan, hypoxanthine, and nicotinate. [26., 27.]
Oral administration of B. longum NCC3001 to depression patients reduces depression scores and alters brain activity. [22.]
B. longum 1714™ modulates brain activity by regulating resting neural activity and neural responses in healthy humans [2., 28.]
The levels of bifidobacteria are generally lower in individuals with autism compared to healthy controls. [16.]
Bifidobacterium spp. are beneficial bacteria that synthesize gamma-Aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain. Lower levels of bifidobacteria in autistic children are associated with reduced GABA synthesis, which may contribute to ASD symptoms. [16.]
Bifidobacterium spp. facilitate the absorption of vitamins and minerals. [5.]
They also have a robust system for breaking down complex carbohydrates from food and intestinal mucous into short-chain fatty acids that are readily absorbed by the host, providing energy and nutritive products for both bacterial growth and host metabolism [15., 24.]
Bifidobacterium spp. also produce various acids and metabolites that facilitate the absorption of ions and vitamins, such as vitamin K. [15.]
One study of 40 pediatric patients, divided into treatment and control groups, demonstrated significant improvements in the absorption of vitamins and minerals over a 10-week period compared to the placebo. [4.]
Specifically, calcium, vitamin D, Vitamin A, zinc, and iron all showed some increase with regular use of a probiotic containing Bifidobacterium spp. and Lactobacillus. [4.]
Bifidobacterium spp. have been shown to promote bone density and repair. [5.]
One study demonstrated that B. longum supplementation in ovariectomized rats effectively prevented bone loss by enhancing bone formation and reducing bone resorption. [19.]
This was achieved through improved bone microstructure and upregulation of key genes associated with bone health.
These findings suggest that B. longum could be a potential therapeutic agent for preventing postmenopausal osteoporosis.
Some strains of Bifidobacterium spp. may reduce host fat accumulation, and promote metabolic health.
Supplementing a cholesterol-enriched diet with yoghurt containing B. pseudocatenulatum G4 or B. longum BB536 effectively reduces plasma cholesterol levels, lipid peroxidation, and increases faecal bile acid excretion in rats. [1.]
Consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145, both viable and heat-killed forms, improves anthropometric adiposity biomarkers in abdominally obese individuals, especially in women. An increase in the gut Akkermansia genus appears as a possible mechanism involved. [21.]
Another study focusing on B. lactis 420 demonstrated reduced fat mass and improved glucose tolerance in obese and diabetic mice. [25.]
The probiotic's benefits are linked to decreased gut microbial translocation, reduced plasma LPS, and lowered tissue inflammation, suggesting a mechanism involving improved intestinal barrier function and reduced endotoxaemia. [25.]
This study highlights the potential of B. lactis 420 as a probiotic treatment for metabolic diseases.
Bifidobacterium spp. levels are assessed in stool samples. Stool samples may be collected from the comfort of home.
Testing may require avoidance of certain medications and/or supplements including probiotics prior to sample collection. It is important to consult with the ordering provider for full test preparation instructions.
It is important to consult with the laboratory company used for test interpretation.
One lab company provides the following reference range for Bifidobacterium spp. spp. levels: 6.7e7org/g [23.]
High levels of Bifidobacterium spp. in the gut microbiome are generally associated with a healthy state and favorable metabolic outcomes.
In the setting of symptoms of dysbiosis or SIBO such as gas, bloating, and/or abdominal pain, further assessment and possible treatments should be considered.
Patients in this scenario who are using probiotics should consider stopping their probiotics.
In rare clinical settings involving either the very young or the very elderly who also have impaired intestinal barriers and/or are immunocompromised, Bifidobacterium spp. may become invasive and cause bacteremia. [9.]
Generally, Bifidobacterium spp. are considered to be beneficial. Low levels of Bifidobacterium spp. have been associated with:
Therefore, maintaining a high abundance of Bifidobacterium spp. in the gut microbiome is generally considered a favorable state, associated with better metabolic health, a lean phenotype, and a lower risk of inflammatory conditions like IBD.
Monitoring Bifidobacterium spp. levels may have clinical significance in assessing gut health, disease risk, and potential therapeutic interventions aimed at restoring a balanced microbiome.
A healthy diet and lifestyle are foundational for microbiome health.
Bifidobacterium spp. are essential beneficial bacteria that play a crucial role in maintaining gut health and overall well-being. This FAQ section addresses common questions about bifidobacteria, their benefits, and how to support their growth in your gut microbiome.
Bifidobacterium spp. are a group of beneficial bacteria that naturally inhabit the human gut. They are particularly important in infants, as Bifidobacterium spp. are some of the first to colonize the infant digestive tract.
Generally speaking, Bifidobacterium spp. are gram-positive, anaerobic microorganisms that play a vital role in maintaining digestive health, supporting the immune system, and promoting overall well-being.
Bifidobacterium spp. contribute to various aspects of health.
They help maintain a balanced gut microbiome, support digestive function, enhance nutrient absorption, and strengthen the gut barrier.
Additionally, bifidobacteria play a role in modulating the immune system, producing vitamins, and potentially reducing inflammation in the body.
You can increase bifidobacteria levels through several methods:
A Bifidobacterium spp. supplement is a probiotic product containing live Bifidobacterium strains. These supplements are designed to introduce beneficial bifidobacteria into your gut microbiome, potentially improving digestive health and overall well-being.
Yes, multiple studies have demonstrated the effectiveness of Bifidobacterium spp. probiotics. They can help prevent and treat gastrointestinal disorders, support immune function, and potentially contribute to overall health.
However, the effectiveness may vary depending on the specific strain and individual factors including the quality of the individual probiotic used.
Some of the most studied and beneficial Bifidobacterium spp. strains include B. bifidum, B. breve, and B. longum. These strains have shown promise in preventing and treating gastrointestinal disorders and supporting overall health.
However, the effectiveness of specific strains may vary depending on the individual and the health condition being addressed.
Research suggests that Bifidobacterium spp. may be beneficial for various health conditions including inflammatory bowel disease, irritable bowel syndrome, antibiotic-associated diarrhea, and certain allergies.
They may also play a role in supporting mental health and metabolic function. However, more research is needed to fully understand their potential in treating specific conditions.
Bifidobacterium spp. are generally considered safe for most people. They are naturally present in the human gut and are commonly found in many fermented foods.
However, individuals with compromised immune systems or severe illnesses should consult with a healthcare professional before starting any probiotic regimen.
Click here to compare testing options and order tests to assess Bifidobacterium spp. spp. levels.
[1.] Al-Sheraji S. H., Ismail A., Manap M. Y., Mustafa S., Yusof R. M., Hassan F. A. (2012). Hypocholesterolaemic Effect of Yoghurt Containing Bifidobacterium Pseudocatenulatum G4 or Bifidobacterium Longum BB536. Food Chem. 135, 356–361. 10.1016/j.foodchem.2012.04.120
[2.] Allen A. P., Hutch W., Borre Y. E., Kennedy P. J., Temko A., Boylan G., et al. (2016). Bifidobacterium Longum 1714 as a Translational Psychobiotic: Modulation of Stress, Electrophysiology and Neurocognition in Healthy Volunteers. Transl Psychiatry 6, e939. 10.1038/tp.2016.191
[3.] Bae E.-A., Han M. J., Song M.-J., Kim D.-H. (2002). Purification of Rotavirus Infection-Inhibitory Protein from Bifidobacterium Breve K-110. Seoul: COREE, REPUBLIQUE DE, Korean Society for Applied Microbiology.
[4.] Ballini A, Gnoni A, De Vito D, et al. Effect of probiotics on the occurrence of nutrition absorption capacities in healthy children: a randomized double-blinded placebo-controlled pilot study. European Review for Medical and Pharmacological Sciences. 2019;23(19):8645-8657. doi:https://doi.org/10.26355/eurrev_201910_19182
[5.] Chen J, Chen X, Ho CL. Recent Development of Probiotic Bifidobacterium spp. for Treating Human Diseases. Front Bioeng Biotechnol. 2021 Dec 22;9:770248. doi: 10.3389/fbioe.2021.770248. PMID: 35004640; PMCID: PMC8727868.
[6.] Chenoll E, Rivero M, Codoñer FM, Martinez-Blanch JF, Ramón D, Genovés S, Moreno Muñoz JA. Complete Genome Sequence of Bifidobacterium longum subsp. infantis Strain CECT 7210, a Probiotic Strain Active against Rotavirus Infections. Genome Announc. 2015 Apr 2;3(2):e00105-15. doi: 10.1128/genomeA.00105-15. PMID: 25838473; PMCID: PMC4384477.
[7.] Corrêa NB, Péret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005 May-Jun;39(5):385-9. doi: 10.1097/01.mcg.0000159217.47419.5b. PMID: 15815206.
[8.] Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013 Nov 15;74(10):720-6. doi: 10.1016/j.biopsych.2013.05.001. Epub 2013 Jun 10. PMID: 23759244.
[9.] Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterium spp.l Infections. Bifidobacterium Bacteremia: Clinical Characteristics and a Genomic Approach To Assess Pathogenicity. J Clin Microbiol. 2017 Jul;55(7):2234-2248. doi: 10.1128/JCM.00150-17. Epub 2017 May 10. PMID: 28490487; PMCID: PMC5483926.
[10.] Fukushima Y, Kawata Y, Mizumachi K, Kurisaki J, Mitsuoka T. Effect of bifidobacteria feeding on fecal flora and production of immunoglobulins in lactating mouse. Int J Food Microbiol. 1999 Feb 18;46(3):193-7. doi: 10.1016/s0168-1605(98)00183-4. PMID: 10100899.
[11.] Hidalgo-Cantabrana C, et al. Bifidobacterium spp. and Their Health-Promoting Effects. Bugs as Drugs. Published online February 1, 2018:73-98. doi:https://doi.org/10.1128/microbiolspec.bad-0010-2016
[12.] Hou, K., Wu, ZX., Chen, XY. et al. Microbiota in health and diseases. Sig Transduct Target Ther 7, 135 (2022). https://doi.org/10.1038/s41392-022-00974-4
[13.] Jang H. M., Jang S.-E., Han M. J., Kim D.-H. (2018). Anxiolytic-like Effect of Bifidobacterium Adolescentis IM38 in Mice with or without Immobilisation Stress. Beneficial microbes 9, 123–132. 10.3920/bm2016.0226
[14.] Jang H.-M., Lee K.-E., Kim D.-H. (2019). The Preventive and Curative Effects of Lactobacillus Reuteri NK33 and Bifidobacterium Adolescentis NK98 on Immobilization Stress-Induced Anxiety/depression and Colitis in Mice. Nutrients 11, 819. 10.3390/nu11040819
[15.] Leahy SC, Higgins DG, Fitzgerald GF, van Sinderen D. Getting better with bifidobacteria. J Appl Microbiol. 2005;98(6):1303-15. doi: 10.1111/j.1365-2672.2005.02600.x. PMID: 15916644.
[16.] Mehra A, Arora G, Sahni G, et al. Gut microbiota and Autism Spectrum Disorder: From pathogenesis to potential therapeutic perspectives. Journal of Traditional and Complementary Medicine. 2022;13(2). doi:https://doi.org/10.1016/j.jtcme.2022.03.001
[17.] Milani C, Turroni F, Duranti S, Lugli GA, Mancabelli L, Ferrario C, van Sinderen D, Ventura M. Genomics of the Genus Bifidobacterium Reveals Species-Specific Adaptation to the Glycan-Rich Gut Environment. Appl Environ Microbiol. 2015 Nov 20;82(4):980-991. doi: 10.1128/AEM.03500-15. PMID: 26590291; PMCID: PMC4751850.
[18.] O'Callaghan A, van Sinderen D. Bifidobacterium spp. and Their Role as Members of the Human Gut Microbiota. Front Microbiol. 2016 Jun 15;7:925. doi: 10.3389/fmicb.2016.00925. PMID: 27379055; PMCID: PMC4908950.
[19.] Parvaneh K, Ebrahimi M, Sabran MR, Karimi G, Hwei AN, Abdul-Majeed S, Ahmad Z, Ibrahim Z, Jamaluddin R. Probiotics (Bifidobacterium longum) Increase Bone Mass Density and Upregulate Sparc and Bmp-2 Genes in Rats with Bone Loss Resulting from Ovariectomy. Biomed Res Int. 2015;2015:897639. doi: 10.1155/2015/897639. Epub 2015 Aug 20. PMID: 26366421; PMCID: PMC4558422.
[20.] Patole SK, Rao SC, Keil AD, Nathan EA, Doherty DA, Simmer KN. Benefits of Bifidobacterium breve M-16V Supplementation in Preterm Neonates - A Retrospective Cohort Study. PLoS One. 2016 Mar 8;11(3):e0150775. doi: 10.1371/journal.pone.0150775. PMID: 26953798; PMCID: PMC4783036.
[21.] Pedret A, Valls RM, Calderón-Pérez L, Llauradó E, Companys J, Pla-Pagà L, Moragas A, Martín-Luján F, Ortega Y, Giralt M, Caimari A, Chenoll E, Genovés S, Martorell P, Codoñer FM, Ramón D, Arola L, Solà R. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019 Sep;43(9):1863-1868. doi: 10.1038/s41366-018-0220-0. Epub 2018 Sep 27. PMID: 30262813; PMCID: PMC6760601.
[22.] Pinto-Sanchez M. I., Hall G. B., Ghajar K., Nardelli A., Bolino C., Lau J. T., et al. (2017). Probiotic Bifidobacterium Longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients with Irritable Bowel Syndrome. Gastroenterology 153, 448–459. e8. 10.1053/j.gastro.2017.05.003
[23.] Rupa Health. GI-MAP + Zonulin Sample Report.pdf. Google Docs. https://drive.google.com/file/d/13LXmPBhXV2Y9paOeE5id2OM2X0V5gJ56/view
[24.] Schell MA, Karmirantzou M, Snel B, Vilanova D, Berger B, Pessi G, Zwahlen MC, Desiere F, Bork P, Delley M, Pridmore RD, Arigoni F. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14422-7. doi: 10.1073/pnas.212527599. Epub 2002 Oct 15. Erratum in: Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9430. PMID: 12381787; PMCID: PMC137899.
[25.] Stenman LK, Waget A, Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes. 2014 Dec;5(4):437-45. doi: 10.3920/BM2014.0014. PMID: 25062610.
[26.] Tian P., Bastiaanssen T. F. S., Song L., Jiang B., Zhang X., Zhao J., et al. (2021). Unraveling the Microbial Mechanisms Underlying the Psychobiotic Potential of a Bifidobacterium Breve Strain. Mol. Nutr. Food Res. 65, 2000704. 10.1002/mnfr.202000704
[27.] Tian P., O'Riordan K. J., Lee Y.-K., Wang G., Zhao J., Zhang H., et al. (2020). Towards a Psychobiotic Therapy for Depression: Bifidobacterium Breve CCFM1025 Reverses Chronic Stress-Induced Depressive Symptoms and Gut Microbial Abnormalities in Mice. Neurobiol. Stress 12, 100216. 10.1016/j.ynstr.2020.100216
[28.] Wang H., Braun C., Murphy E. F., Enck P. (2019). Bifidobacterium Longum 1714 Strain Modulates Brain Activity of Healthy Volunteers during Social Stress. Am. J. Gastroenterol. 114, 1152–1162. 10.14309/ajg.0000000000000203